Drug preparation, injection-related infections, and harm reduction practices among a national sample of individuals entering treatment for opioid use disorder

Harm Reduction Journal
Laura R. Marks1, Michael J. Durkin1, Kelly Ayres2, Matthew S. Ellis2
1Division of Infectious Disease, Washington University School of Medicine, Campus Box 8051, 4523 Clayton Avenue, St. Louis, MO, USA
2Department of Psychiatry, Washington University School of Medicine, St. Louis, Mo., USA

Tóm tắt

Abstract Background The rise in injection drug use in the USA has led to an increase in injection site infections. We performed a national survey of people who use drugs to evaluate common drug use preparation, harm reduction practices, and experiences with injection site infections. Methods A survey was disseminated to members of the Survey of Key Informants’ Patients Program from 2021 to 2022 and distributed to patients 18 years or older newly entering one of 68 substance use disorder treatment programs across the USA with a primary diagnosis of an opioid use disorder. Participants were surveyed about practices when preparing and using drugs, along with self-reported infections and drug use complications. Results 1289 participants responded to the survey. Sexually transmitted infections were common, with 37.6% reporting ever having had any sexually transmitted infection. Injection-associated infections had affected 63.4% of participants who had ever used injection drugs. Many respondents reported not seeking professional medical assistance for infection management, including 29% draining abscesses without seeking medical care and 22.8% obtaining antibiotics through non-healthcare sources. Non-sterile injection practices included sharing needles with others who were febrile or ill (18%), using needles previously used to drain wounds/abscesses (9.9%) for subsequent injection drug use, and licking needles (21.2%). Conclusion Patients entering treatment for opioid use disorder reported a high burden of infectious diseases. A number of easily-modifiable high risk behaviors for developing injection-related infections were identified. Efforts are needed to disseminate targeted harm reduction education to PWID on how to reduce their risks for injection-related infections.

Từ khóa


Tài liệu tham khảo

Conrad C, Bradley HM, Broz D, et al. Community outbreak of HIV infection linked to injection drug use of oxymorphone-Indiana, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(16):443–4.

Alpren C, Dawson EL, John B, et al. Opioid use fueling HIV transmission in an urban setting: an outbreak of HIV infection among people who inject drugs-Massachusetts, 2015–2018. Am J Public Health. 2020;110(1):37–44.

Peters PJ, Pontones P, Hoover KW, et al. HIV infection linked to injection use of oxymorphone in Indiana, 2014–2015. N Engl J Med. 2016;375(3):229–39.

Degenhardt L, Peacock A, Colledge S, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017;5(12):e1192–207.

Levitt A, Mermin J, Jones CM, See I, Butler JC. Infectious diseases and injection drug use: public health burden and response. J Infect Dis. 2020;222(Supplement_3):S213–7.

Larney S, Peacock A, Mathers BM, Hickman M, Degenhardt L. A systematic review of injecting-related injury and disease among people who inject drugs. Drug Alcohol Depend. 2017;171:39–49.

See I, Gokhale RH, Geller A, et al. National public health burden estimates of endocarditis and skin and soft-tissue infections related to injection drug use: a review. J Infect Dis. 2020;222(Suppl 5):S429–36.

Binswanger IA, Kral AH, Bluthenthal RN, Rybold DJ, Edlin BR. High prevalence of abscesses and cellulitis among community-recruited injection drug users in San Francisco. Clin Infect Dis. 2000;30(3):579–81.

Cruz I, Morales MA, Noguer I, Rodríguez A, Alvar J. Leishmania in discarded syringes from intravenous drug users. Lancet. 2002;359(9312):1124–5.

Middaugh N, Edwards L, Chatham-Stephens K, Arguello DF. Wound botulism among persons who inject black tar heroin in New Mexico, 2016. Front Public Health. 2021;9:744179.

Palmateer NE, Hope VD, Roy K, et al. Infections with spore-forming bacteria in persons who inject drugs, 2000–2009. Emerg Infect Dis. 2013;19(1):29–34.

Kimura AC, Higa JI, Levin RM, Simpson G, Vargas Y, Vugia DJ. Outbreak of necrotizing fasciitis due to Clostridium sordellii among black-tar heroin users. Clin Infect Dis Offic Publ Infect Dis Soc Am. 2004;38(9):e87-91.

Deutscher M, Perlman DC. Why some injection drug users lick their needles: a preliminary survey. Int J Drug Policy. 2008;19(4):342–5.

Valenciano SJ, McMullen C, Torres S, Smelser C, Matanock A, Van Beneden C. Notes from the field: identifying risk behaviors for invasive group a streptococcus infections among persons who inject drugs and persons experiencing homelessness—New Mexico, May 2018. MMWR Morb Mortal Wkly Rep. 2019;68(8):205–6.

Marks LRCJ, Wildenthal JA, Wallace MA, Sawhney S, Ransom EM, Durkin MJ, Henderson JP, Burnham CAD, Dantas G. Staphylococcus aureus injection drug use-associated bloodstream infections are propagated by community outbreaks of diverse lineages. Commun Med. 2021;1:52.

Packer S, Pichon B, Thompson S, et al. Clonal expansion of community-associated meticillin-resistant Staphylococcus aureus (MRSA) in people who inject drugs (PWID): prevalence, risk factors and molecular epidemiology, Bristol, United Kingdom, 2012 to 2017. Euro Surveill Bull Eur Commun Dis 2019; 24(13).

Craven DE, Rixinger AI, Goularte TA, McCabe WR. Methicillin-resistant Staphylococcus aureus bacteremia linked to intravenous drug abusers using a “shooting gallery.” Am J Med. 1986;80(5):770–6.

Murphy EL, DeVita D, Liu H, et al. Risk factors for skin and soft-tissue abscesses among injection drug users: a case-control study. Clin Infect Dis. 2001;33(1):35–40.

Jawa R, Stein MD, Anderson B, et al. Association of skin infections with sharing of injection drug preparation equipment among people who inject drugs. Int J Drug Policy. 2021;94:103198.

Harvey L, Boudreau J, Sliwinski SK, et al. Six moments of infection prevention in injection drug use: an educational toolkit for clinicians. Open Forum Infect Dis. 2022. https://doi.org/10.1093/ofid/ofab631.

Barocas JA, Eftekhari Yazdi G, Savinkina A, et al. Long-term infective endocarditis mortality associated with injection opioid use in the United States: a modeling study. Clin Infect Dis Offic Publ Infect Dis Soc Am. 2021;73(11):e3661–9.

Dart RC, Surratt HL, Cicero TJ, et al. Trends in opioid analgesic abuse and mortality in the United States. New England J Med. 2015;372(3):241–8.

McDaniel H, Severtson S, BucherBartelson B, Green J, Dart RJRSTR. Comparing prescription opioids, methadone, and heroin endorsement rates from the treatment episode data set to the RADARS system treatment center programs. 2016: Q3.

Seval N, Eaton E, Springer SA. Beyond antibiotics: a practical guide for the infectious disease physician to treat opioid use disorder in the setting of associated infectious diseases. Open Forum Infect Dis. 2020;7(1):ofz539.

Kasper KJ, Manoharan I, Hallam B, et al. A controlled-release oral opioid supports S. aureus survival in injection drug preparation equipment and may increase bacteremia and endocarditis risk. PLoS ONE. 2019;14(8):0219777.

Desai R, Pannaraj PS, Agopian J, Sugar CA, Liu GY, Miller LG. Survival and transmission of community-associated methicillin-resistant Staphylococcus aureus from fomites. Am J Infect Control. 2011;39(3):219–25.

Bassetti S, Battegay M. Staphylococcus aureus infections in injection drug users: risk factors and prevention strategies. Infection. 2004;32(3):163–9.

Serota DP, Barocas JA, Springer SA. Infectious complications of addiction: a call for a new subspecialty within infectious diseases. Clin Infect Dis Offic Publ Infect Dis Soc Am. 2020;70(5):968–72.

Fracasso Francis SM, Beekmann SE, Polgreen PM, et al. Harm reduction: a missing piece in holistic ID care for patients who inject drugs. Open Forum Infect Dis. 2022. https://doi.org/10.1093/ofid/ofac492.090.

Sikka MK, Gore S, Vega T, Strnad L, Gregg J, Englander H. “OPTIONS-DC”, a feasible discharge planning conference to expand infection treatment options for people with substance use disorder. BMC Infect Dis. 2021;21(1):772.

Farooqui AM, Arya A, Singh A, Dalal PK. Psychiatric comorbidity, psychosocial problems, and functioning of people who inject opioids: an observational study. Addict Health. 2022;14(3):218–23.

Ahern J, Stuber J, Galea S. Stigma, discrimination and the health of illicit drug users. Drug Alcohol Depend. 2007;88(2–3):188–96.

Summers PJ, Hellman JL, MacLean MR, Rees VW, Wilkes MS. Negative experiences of pain and withdrawal create barriers to abscess care for people who inject heroin: a mixed methods analysis. Drug Alcohol Depend. 2018;190:200–8.

Gilbert AR, Hellman JL, Wilkes MS, Rees VW, Summers PJ. Self-care habits among people who inject drugs with skin and soft tissue infections: a qualitative analysis. Harm Reduct J. 2019;16(1):69.

Colledge-Frisby S, Ottaviano S, Webb P, et al. Global coverage of interventions to prevent and manage drug-related harms among people who inject drugs: a systematic review. Lancet Glob Health. 2023;11(5):e673–83.

Davis CS, Carr DH, Samuels EA. Paraphernalia laws, criminalizing possession and distribution of items used to consume illicit drugs, and injection-related harm. Am J Public Health. 2019;109(11):1564–7.

Syringe exchange programs—United States, 2008. MMWR Morbidity and mortality weekly report 2010; 59(45): 1488–91.

Lambdin BH, Bluthenthal RN, Wenger LD, et al. Overdose education and naloxone distribution within syringe service programs: United States, 2019. MMWR Morb Mortal Wkly Rep. 2020;69(33):1117–21.

Bartholomew TS, Tookes HE, Chueng TA, et al. Availability of telehealth-based services at syringe services programs under the COVID-19 Public Health Emergency. Harm Reduct J. 2023;20(1):122.

Behrends CN, Nugent AV, Des Jarlais DC, Frimpong JA, Perlman DC, Schackman BR. Availability of HIV and HCV on-site testing and treatment at syringe service programs in the United States. J Acquired Immune Deficiency Syndrom. 2018;79(2):e76–8.

Ahmadi K, Javadinia SA, Saadat SH, Ramezani MA, Sedghijalal H. Triangular relationship among risky sexual behavior, addiction, and aggression: a systematic review. Electron Phys. 2017;9(8):5129–37.

Siegal HA, Falck RS, Wang J, Carlson RG. History of sexually transmitted diseases infection. Drug-Sex Behav Condoms Among Midwestern Inject Drugs Crack Cocaine. 1996;23(4):277–82.

Reno H, Fox B, Highfill C, et al. The emerging intersection between injection drug use and early Syphilis in Nonurban Areas of Missouri, 2012–2018. J Infect Dis. 2020;222(Suppl 5):S465–70.

Carlson JM, Tannis A, Woodworth KR, et al. Substance use among persons with syphilis during pregnancy: Arizona and Georgia, 2018–2021. MMWR Morb Mortal Wkly Rep. 2023;72(3):63–7.

Recent HIV Clusters and Outbreaks Across the United States Among People Who Inject Drugs and Considerations During the COVID-19 Pandemic. CDC Heatlh Alert Network, 2022.

Rich KM, Solomon DAJNE. Medical complications of injection drug use—Part I. 2023; 2(2): EVIDra2200292.

Marks LR, Reno H, Liang SY, et al. Value of packaged testing for sexually transmitted infections for persons who inject drugs hospitalized with serious injection-related infections. Open Forum Infect Dis. 2021. https://doi.org/10.1093/ofid/ofab489.

Thông tin
Thông tin xuất bản

Harm Reduction Journal

Thông tin tác giả